cancer research

He took on the leukemia nobody wanted, helped transform CML from a fatal disease into a chronic condition, and built a network in Europe that changed how leukemia research is done across the world. More than five decades into his…

After more than four decades under the leadership of Alberto Costa, the European School of Oncology enters a new chapter with Rossella Blasi as CEO. The transition brings together the legacy of Umberto Veronesi’s founding vision and the challenge of…

Science is moving at extraordinary speed. We can identify mutations once invisible, develop drugs that destroy proteins previously considered untouchable, and transform diagnoses that once offered little hope. Yet a patient can still wait too long for treatment. A brilliant…

The history of pediatric oncology is one of extraordinary progress. Children who once had little chance of surviving cancer are now growing into adulthood, building careers, raising families and imagining futures that previous generations could not. But progress has also…

10 Years of PICI: From Discovery to Impact Ten years ago, the Parker Institute for Cancer Immunotherapy (PICI) was created around a bold premise: that progress in cancer research could be accelerated by changing not only what science pursued, but…

A mouse model of lung cancer has uncovered a potential new therapeutic strategy for treating cancer cachexia. The study, published in Science on 2 July, found that Lkb1-mutant lung tumours—a common subtype of lung cancer—can communicate directly with the brain…

Large meta-analysis suggests patient-reported outcomes complement traditional clinical assessment. Despite advances in imaging, molecular profiling, and biomarkers, accurately estimating how long a patient with cancer is likely to survive remains challenging. Now, a large analysis involving data from more than…

We often describe progress in oncology through the language of discovery. Scientific breakthroughs. Technological innovation. Deeper biological insight. These advances have transformed medicine, helping millions of people live longer and better than ever before. Yet alongside every scientific breakthrough, a…

Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…